Specifically, IL-21 treatment of type I latency Burkitt lymphoma cells inhibits cell proliferation, whereas in type III latency LCL and Burkitt lymphoma cell lines it induces plasma cell differentiation9. Here, IL21 is linked to Burkitt lymphoma.